ISebe leHlabathi

Ngomhla we-11 kuJuni, uKelun-Biotech ubhengeze ukuba i-TROP2 ADC drug sac-TMT (佳泰莱) eyilwe ngokuzimeleyo, kunye ne-PD-L1 monoclonal antibody tagitanlimab (科泰莱), inikwe iBreakthrough Therapy Designation (BTD) yiZiko loVavanyo lwaMayeza (CDE) leNational Med...Funda ngokugqithisileyo»

Ngomhla wama-29 kuCanzibe, iNational Medical Products Administration (NMPA) yavuma ukuthengiswa kweZanidatamab, engeniswe yiBeiGene, ukuze kunyangwe izigulane ezinomhlaza we-biliary tract ongenakunyangwa (BTC) okwindawo ethile okanye osasazekayo, ezazikhe zafumana unyango lwenkqubo kwaye zibonakalise i-HER2 ephezulu...Funda ngokugqithisileyo»

Ngomhla wesi-4 kweyeSilimela, ngo-2025, u-Akeso ubhengeze ukuba i-National Medical Products Administration (NMPA) ivumile i-PD-1/CTLA-4 bispecific antibody yenkampani yokuqala kwiklasi, i-cadonilimab, yonyango lokuqala lomhlaza wesibeleko oqhubekayo, ophindaphindayo, okanye osasazekayo, kunye ne-platinu...Funda ngokugqithisileyo»

Ngomhla wama-29 kuCanzibe, iNational Medical Products Administration (NMPA) yavuma i-HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) ukuba ithengiswe. Iboniswa njenge-monotherapy yonyango lwezigulane zabantu abadala ezine-metastatic non-small inclinative non-small ...Funda ngokugqithisileyo»

Ngomhla wama-21 kuCanzibe, ngo-2025, i-InnoCare Pharma yabhengeza ukuba i-China National Medical Products Administration (NMPA) ivumile iMinjuvi® (tafasitamab), i-antibody ye-Fc-modified cytolytic CD19 ejolise kwi-monoclonal antibody eyenziwe ngumntu, kunye ne-lenalidomide, ilandelwe yi-Minjuvi monotherapy, ukuze...Funda ngokugqithisileyo»

Ngomhla wama-22 kuCanzibe, ngo-2025, i-Allist Pharmaceuticals ibhengeze ukuba iyeza layo elitsha i-Airuikai (Glecirasib Citrate Tablets), i-KRAS-G12C inhibitor, livunyiwe ngokusemthethweni ukuba liqaliswe kwimarike yi-National Medical Products Administration (NMPA). Imvume ivumela i-Airuikai ukuba isetyenziswe kunyango...Funda ngokugqithisileyo»

Ngomhla wama-22 kuCanzibe, ngo-2025, uKelun Bio wabhengeza ukuba isicelo sophawu olutsha lwe-trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ekwaziwa ngokuba yi-SKB264/MK – 2870) (®) samkelwa yiZiko loVavanyo lwaMayeza (...Funda ngokugqithisileyo»

Kwidabi Elide Elichasene Nomhlaza, Izixhobo Ezintsha Zokulwa Nomhlaza Ziyavela Ngokuqhubekayo, Zizisa Ithemba Elitsha Kwimfazwe ende phakathi kwabantu nomhlaza, izixhobo ezintsha zokulwa nomhlaza ziyavela emva kwesinye, zizisa ithemba elitsha kwizigulana. Njengesiqalo esitsha esikhanyayo...Funda ngokugqithisileyo»

Ngowama-2021, isigulane esineminyaka engama-67 ubudala esinesifo somhlaza wepancreatic senza ummangaliso wezonyango. Emva kotyando, imijikelo emininzi ye-chemotherapy, kunye nokungaphumeleli konyango lwe-TIL, uvavanyo lweklinikhi lonyango lweeseli ze-TCR-T awathatha inxaxheba kulo lwenze ukuba i-metastases yemiphunga inciphe ngama-72% kwisithuba seenyanga ezi-6...Funda ngokugqithisileyo»

Ngomhla we-12 kuCanzibe, ngo-2025, i-CARsgen ibhengeza idatha yokuqala yeklinikhi ye-CT0596, i-CAR-T ejoliswe kwi-allogeneic BCMA eyenziwe kusetyenziswa iqonga le-THANK-u Plus™. I-CT0596 okwangoku ivavanywa kuphononongo lweklinikhi lokuqala lokuhlola i-relapse/refractory multiple myeloma (R/R MM) okanye i-relapse/refractor...Funda ngokugqithisileyo»

Ngomhla we-9 kuCanzibe, ngo-2025, iHansoh Pharmaceutical yabhengeza ukuba isalathisi esitsha se-Ameile (iipilisi ze-almonertinib mesylate) sivunyiwe ukuba sithengiswe. Isibonakaliso esitsha sesonyango oluncedisayo lwezigulane ezindala ezinomhlaza wamaphaphu ongengoweeseli ezincinci (i-NSCLC) ezineethumba ezine-epidermal growth factor re...Funda ngokugqithisileyo»

Ngomhla we-1 kuMeyi, ngo-2025, iHansoh Pharmaceutical ibhengeze ukuba i-B7-H4-target antibody-drug conjugate (ADC) HS-20089 eyenzelwe yona yeQela ukuze ijojwe ifumene imvume yokuba ifakwe njenge-Breakthrough-Therapy-Designated Drug yi-National Medical Products Administration (NMPA) yaseTshayina,...Funda ngokugqithisileyo»